Therapeutic Response

TP53 deletion status confers therapeutic sensitivity to Idelalisib in combination with Rituximab in patients with Chronic Lymphocytic Leukemia.

Statements

Source and description
Zydelig (idelalisib) [product information]. EMA. The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.